You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Primary epithelioid haemangioendothelioma of the eyelid
  1. H Tsuji1,2,
  2. H Kanda3,
  3. H Kashiwagi4,
  4. T Mimura2
  1. 1Department of Ophthalmology, The Cancer Institute of JFCR, Tokyo, Japan
  2. 2Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
  3. 3Department of Pathology, The Cancer Institute of JFCR, Tokyo, Japan
  4. 4Department of Ophthalmology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan
  1. Correspondence to Dr H Tsuji, Department of Ophthalmology, The Cancer Institute Hospital of JFCR, 3-10-6 Ariake, Kouto-ku, Tokyo, 135-8550 Japan; tsuji-tky{at}umin.ac.jp

https://doi.org/10.1136/bjo.2008.156497

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Epithelioid haemangioendothelioma (EHE) is a rare vascular tumour of intermediate malignancy that lies on the spectrum of progression from haemangioma to angiosarcoma.1 Weiss and Enzinger1 initially described EHE in 1982. EHE can arise in many organs and has been described as developing in the liver, bone, skin, lung and soft tissues.2 However, ocular involvement is rare. Ocular haemangioendothelioma has been reported and included as differential diagnosis of masquerade of eyelid tumours in a review of cases from 1989 by de Keizer and Scheffer.3 The cases of ocular EHE were described by Lyon et al4 in 1992. Here, we describe a rare case of EHE affecting an eyelid.

    Case report

    A 34-year-old woman presented with a 2-year history of a slightly painful left upper eyelid. She was initially treated with topical medications for several months, but her symptoms became progressively worse. She was then referred to The Cancer Institute Hospital of JFCR for assessment and management of her treatment-resistant suspected haemangioma. The first examination revealed a best-corrected visual acuity of 20/20 …

    View Full Text

    Footnotes

    • Competing interests The authors have no commercial or proprietary interest in the product or company described in the current article.

    • Ethics approval Ethics approval was provided by University of Tokyo Graduate School of Medicine.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.